ZA200006465B - Novel formulation containing paroxetine. - Google Patents

Novel formulation containing paroxetine. Download PDF

Info

Publication number: ZA200006465B
Authority: ZA; South Africa
Prior art keywords: paroxetine; excipients; anhydrous; paroxetine hydrochloride; capsules
Prior art date: 1998-05-13

Application number

ZA200006465A

Other languages

English (en)

Inventor

David Philip Elder

Graham Stanley Leonard

Original Assignee

Smithkline Beecham Plc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-05-13

Filing date

2000-11-09

Publication date

2001-11-09

2000-11-09 Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc

2001-11-09 Publication of ZA200006465B publication Critical patent/ZA200006465B/en

Links

AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 title claims description 75
AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 title claims description 19
229960002296 paroxetine Drugs 0.000 title claims description 19
239000000203 mixture Substances 0.000 title description 10
238000009472 formulation Methods 0.000 title description 9
239000002775 capsule Substances 0.000 claims description 28
229960005183 paroxetine hydrochloride Drugs 0.000 claims description 28
238000000034 method Methods 0.000 claims description 21
239000000546 pharmaceutical excipient Substances 0.000 claims description 11
238000007907 direct compression Methods 0.000 claims description 8
125000005456 glyceride group Chemical group 0.000 claims description 8
239000000463 material Substances 0.000 claims description 8
FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 6
238000006243 chemical reaction Methods 0.000 claims description 6
-1 monosaccharide sugars Chemical class 0.000 claims description 6
239000010773 plant oil Substances 0.000 claims description 6
239000007787 solid Substances 0.000 claims description 5
235000000346 sugar Nutrition 0.000 claims description 5
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 4
239000001913 cellulose Substances 0.000 claims description 4
239000007788 liquid Substances 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
239000002274 desiccant Substances 0.000 claims description 3
150000002191 fatty alcohols Chemical class 0.000 claims description 3
230000002209 hydrophobic effect Effects 0.000 claims description 3
239000008101 lactose Substances 0.000 claims description 3
238000002360 preparation method Methods 0.000 claims description 3
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
229920000881 Modified starch Polymers 0.000 claims description 2
229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
150000001408 amides Chemical class 0.000 claims description 2
235000014113 dietary fatty acids Nutrition 0.000 claims description 2
150000002148 esters Chemical class 0.000 claims description 2
239000000194 fatty acid Substances 0.000 claims description 2
229930195729 fatty acid Natural products 0.000 claims description 2
150000004665 fatty acids Chemical class 0.000 claims description 2
150000002334 glycols Chemical class 0.000 claims description 2
229920003124 powdered cellulose Polymers 0.000 claims description 2
235000019814 powdered cellulose Nutrition 0.000 claims description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 14
235000019359 magnesium stearate Nutrition 0.000 description 7
239000000725 suspension Substances 0.000 description 7
239000007903 gelatin capsule Substances 0.000 description 6
OIQOAYVCKAHSEJ-UHFFFAOYSA-N 2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol;hexadecanoic acid;octadecanoic acid Chemical compound OCCOCC(OCCO)COCCO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O OIQOAYVCKAHSEJ-UHFFFAOYSA-N 0.000 description 4
VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 4
244000105624 Arachis hypogaea Species 0.000 description 3
GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
239000000832 lactitol Substances 0.000 description 3
235000010448 lactitol Nutrition 0.000 description 3
229960003451 lactitol Drugs 0.000 description 3
239000000843 powder Substances 0.000 description 3
RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
235000017060 Arachis glabrata Nutrition 0.000 description 2
235000010777 Arachis hypogaea Nutrition 0.000 description 2
235000018262 Arachis monticola Nutrition 0.000 description 2
244000060011 Cocos nucifera Species 0.000 description 2
235000013162 Cocos nucifera Nutrition 0.000 description 2
229920000742 Cotton Polymers 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
244000068988 Glycine max Species 0.000 description 2
235000010469 Glycine max Nutrition 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
239000000935 antidepressant agent Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
238000007906 compression Methods 0.000 description 2
230000006835 compression Effects 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
239000012458 free base Substances 0.000 description 2
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
229960001375 lactose Drugs 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
239000003921 oil Substances 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
235000020232 peanut Nutrition 0.000 description 2
RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
235000003911 Arachis Nutrition 0.000 description 1
208000032841 Bulimia Diseases 0.000 description 1
206010006550 Bulimia nervosa Diseases 0.000 description 1
208000020401 Depressive disease Diseases 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
239000004166 Lanolin Substances 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
208000008589 Obesity Diseases 0.000 description 1
208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
240000007817 Olea europaea Species 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
229920002582 Polyethylene Glycol 600 Polymers 0.000 description 1
206010036618 Premenstrual syndrome Diseases 0.000 description 1
235000004443 Ricinus communis Nutrition 0.000 description 1
206010039966 Senile dementia Diseases 0.000 description 1
206010041250 Social phobia Diseases 0.000 description 1
240000006474 Theobroma bicolor Species 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
229960004977 anhydrous lactose Drugs 0.000 description 1
208000022531 anorexia Diseases 0.000 description 1
230000001430 anti-depressive effect Effects 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
235000013871 bee wax Nutrition 0.000 description 1
239000012166 beeswax Substances 0.000 description 1
239000007963 capsule composition Substances 0.000 description 1
235000013869 carnauba wax Nutrition 0.000 description 1
239000004203 carnauba wax Substances 0.000 description 1
229960000541 cetyl alcohol Drugs 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
206010061428 decreased appetite Diseases 0.000 description 1
238000007908 dry granulation Methods 0.000 description 1
230000000694 effects Effects 0.000 description 1
UUXNRWQEPOCOIW-UHFFFAOYSA-N ethanol;octadecanamide Chemical compound CCO.CCCCCCCCCCCCCCCCCC(N)=O UUXNRWQEPOCOIW-UHFFFAOYSA-N 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
229940100242 glycol stearate Drugs 0.000 description 1
235000019388 lanolin Nutrition 0.000 description 1
229940039717 lanolin Drugs 0.000 description 1
206010027599 migraine Diseases 0.000 description 1
235000020824 obesity Nutrition 0.000 description 1
IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
229920000059 polyethylene glycol stearate Polymers 0.000 description 1
201000000484 premenstrual tension Diseases 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
238000003908 quality control method Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
238000003860 storage Methods 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
238000005550 wet granulation Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Neurology (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Inorganic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicinal Preparation (AREA)

ZA200006465A 1998-05-13 2000-11-09 Novel formulation containing paroxetine. ZA200006465B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB9810180.1A GB9810180D0 (en)	1998-05-13	1998-05-13	Novel formulation

Publications (1)

Publication Number	Publication Date
ZA200006465B true ZA200006465B (en)	2001-11-09

Family

ID=10831926

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200006465A ZA200006465B (en)	1998-05-13	2000-11-09	Novel formulation containing paroxetine.

Country Status (20)

Country	Link
EP (1)	EP1077685A2 (xx)
JP (1)	JP2002514593A (xx)
KR (1)	KR20010043545A (xx)
CN (1)	CN1309557A (xx)
AP (1)	AP2000001985A0 (xx)
AU (1)	AU3941099A (xx)
BG (1)	BG105011A (xx)
BR (1)	BR9910402A (xx)
CA (1)	CA2331849A1 (xx)
EA (1)	EA200001173A1 (xx)
GB (1)	GB9810180D0 (xx)
HU (1)	HUP0101931A3 (xx)
ID (1)	ID27018A (xx)
IL (1)	IL139596A0 (xx)
NO (1)	NO20005681L (xx)
PL (1)	PL344872A1 (xx)
SK (1)	SK16972000A3 (xx)
TR (1)	TR200003351T2 (xx)
WO (1)	WO1999058116A2 (xx)
ZA (1)	ZA200006465B (xx)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE50011819D1 (de) *	1999-03-12	2006-01-12	Aesica Pharmaceuticals Ltd	Stabile pharmazeutische anwendungsform für paroxetin-anhydrat
HU226912B1 (en) *	2000-04-07	2010-03-01	Richter Gedeon Nyrt	New paroxetin salt and medicament containing it
JP6062422B2 (ja) *	2012-03-29	2017-01-18	杏林製薬株式会社	カプセル製剤
DE102013207447A1 (de)	2013-04-24	2014-10-30	Evonik Degussa Gmbh	Verfahren und Vorrichtung zur Herstellung von Octachlortrisilan
CN103520131B (zh) *	2013-10-12	2019-05-14	浙江华海药业股份有限公司	盐酸帕罗西汀半水合物胶囊的制备方法
CN103961333B (zh) *	2014-05-07	2020-02-21	浙江华海药业股份有限公司	甲磺酸帕罗西汀胶囊及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP3768536B2 (ja) *	1995-04-03	2006-04-19	アボツト・ラボラトリーズ	低温溶融性薬物と制御放出のための添加物との均質混合物
GB9724544D0 (en) *	1997-11-21	1998-01-21	Smithkline Beecham Plc	Novel Formulation

1998
- 1998-05-13 GB GBGB9810180.1A patent/GB9810180D0/en not_active Ceased
1999
- 1999-05-13 EP EP99922303A patent/EP1077685A2/en not_active Withdrawn
- 1999-05-13 IL IL13959699A patent/IL139596A0/xx unknown
- 1999-05-13 HU HU0101931A patent/HUP0101931A3/hu unknown
- 1999-05-13 CA CA002331849A patent/CA2331849A1/en not_active Abandoned
- 1999-05-13 SK SK1697-2000A patent/SK16972000A3/sk unknown
- 1999-05-13 AU AU39410/99A patent/AU3941099A/en not_active Abandoned
- 1999-05-13 CN CN99808548A patent/CN1309557A/zh active Pending
- 1999-05-13 KR KR1020007012660A patent/KR20010043545A/ko not_active Withdrawn
- 1999-05-13 ID IDW20002329A patent/ID27018A/id unknown
- 1999-05-13 WO PCT/GB1999/001522 patent/WO1999058116A2/en not_active Ceased
- 1999-05-13 PL PL99344872A patent/PL344872A1/xx unknown
- 1999-05-13 EA EA200001173A patent/EA200001173A1/ru unknown
- 1999-05-13 JP JP2000547967A patent/JP2002514593A/ja active Pending
- 1999-05-13 BR BR9910402-4A patent/BR9910402A/pt not_active Application Discontinuation
- 1999-05-13 AP APAP/P/2000/001985A patent/AP2000001985A0/en unknown
- 1999-05-13 TR TR2000/03351T patent/TR200003351T2/xx unknown
2000
- 2000-11-09 ZA ZA200006465A patent/ZA200006465B/en unknown
- 2000-11-10 NO NO20005681A patent/NO20005681L/no not_active Application Discontinuation
- 2000-11-30 BG BG105011A patent/BG105011A/xx unknown

Also Published As

Publication number	Publication date
NO20005681D0 (no)	2000-11-10
ID27018A (id)	2001-02-22
PL344872A1 (en)	2001-11-19
SK16972000A3 (sk)	2001-06-11
TR200003351T2 (tr)	2001-03-21
BG105011A (en)	2001-07-31
GB9810180D0 (en)	1998-07-08
EA200001173A1 (ru)	2001-04-23
AU3941099A (en)	1999-11-29
HUP0101931A3 (en)	2002-10-28
JP2002514593A (ja)	2002-05-21
KR20010043545A (ko)	2001-05-25
HUP0101931A2 (hu)	2002-04-29
WO1999058116A3 (en)	2000-02-17
CN1309557A (zh)	2001-08-22
NO20005681L (no)	2000-12-01
EP1077685A2 (en)	2001-02-28
AP2000001985A0 (en)	2000-12-31
IL139596A0 (en)	2002-02-10
WO1999058116A2 (en)	1999-11-18
BR9910402A (pt)	2001-01-09
CA2331849A1 (en)	1999-11-18

Publication	Publication Date	Title
US6524615B2 (en)	2003-02-25	Controlled release pharmaceutical composition
US6491950B1 (en)	2002-12-10	Controlled release pharmaceutical composition
US5472707A (en)	1995-12-05	High dose ranolazine formulations
AU748396B2 (en)	2002-06-06	Composition
AU611637B2 (en)	1991-06-20	Sustained release formulations containing 4-(1-methyl-4- piperidylidene)-4H-benzo(4,5)-cyclohepta(1,2-b)thiophen- 10(9H)-one
ZA200006465B (en)	2001-11-09	Novel formulation containing paroxetine.
US5705506A (en)	1998-01-06	Pharmaceutical compositions of alkylsulphonamides 5HT1 agonists for rectal administration
US8901128B2 (en)	2014-12-02	Pharmaceutical compositions of ranolazine
US20110196032A1 (en)	2011-08-11	Pharmaceutical Dosage Form of an Antidepressant
SK7342000A3 (en)	2000-12-11	Formulations comprising dissolved paroxetine
AU2003224419A1 (en)	2003-09-09	Orally administrable pharmaceutical formulation
MXPA00011153A (en)	2001-07-31	Novel formulation containing paroxetine
CZ20004185A3 (cs)	2001-05-16	Nový prostředek obsahující paroxetin
AU3940999A (en)	1999-11-29	Novel formulation containing paroxetine
CA2367402C (en)	2010-11-23	Stable pharmaceutical dosage form for paroxetine anhydrate
HUT77381A (hu)	1998-04-28	Eljárás növekedési hormonok hatásainak inhibiálására alkalmas benzotiofén-származékokat tartalmazó gyógyszerkészítmények előállítására
EA003584B1 (ru)	2003-06-26	Способ стимуляции отказа от курения или его снижения или предупреждения возобновления курения и применение пароксетина или его фармацевтически приемлемых солей или сольватов для получения лекарственного средства
MXPA00011154A (en)	2001-12-04	Novel formulation containing paroxetine
MXPA00008849A (en)	2001-07-09	Composition
CA2310407A1 (en)	1999-06-03	Formulations comprising dissolved paroxetine